Cambridge Investment Research Advisors’s BridgeBio Pharma BBIO Stock Holding History

Cambridge Investment Research Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.29M	Buy	30,727 +1,668	+6%	+$117K	0.01%	1573
2026 Q1	$2.16M	Sell	29,059 -15,751	-35%	-$1.14M	0.01%	1534
2025 Q4	$3.43M	Sell	44,810 -2,846	-6%	-$187K	0.01%	1142
2025 Q3	$2.48M	Buy	47,656 +5,569	+13%	+$272K	0.01%	1347
2025 Q2	$1.82M	Buy	42,087 +11,285	+37%	+$410K	0.01%	1499
2025 Q1	$1.06M	Buy	30,802 +6,997	+29%	+$236K	﹤0.01%	1816
2024 Q4	$653K	Buy	23,805 +8,542	+56%	+$221K	﹤0.01%	2208
2024 Q3	$389K	Buy	+15,263	New	+$401K	﹤0.01%	2617

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Cambridge Investment Research Advisors's BBIO Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its BridgeBio Pharma (BBIO) stake by 5.7% in Q2 2026, buying an estimated $117K and bringing the position to 30,727 shares worth $2.29M. The position accounts for 0.01% of the portfolio, ranked #1573.

Cambridge Investment Research Advisors first reported a position in BBIO in Q3 2024 and has held it in 8 quarters since. The position peaked at $3.43M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Cambridge Investment Research Advisors held 30,727 shares of BridgeBio Pharma worth $2.29M as of Q2 2026.
Cambridge Investment Research Advisors bought 1,668 BridgeBio Pharma shares in Q2 2026, an estimated $117K.
BridgeBio Pharma made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1573 holding.
Cambridge Investment Research Advisors first reported a position in BridgeBio Pharma in Q3 2024 and has held it in 8 quarters since.
Cambridge Investment Research Advisors's BridgeBio Pharma position peaked at $3.43M in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.